证券代码：300899 证券简称：*ST凯鑫 公告编号：2025-043 上海凯鑫分离技术股份有限公司 第四届董事会第九次会议决议公告 1、上海凯鑫分离技术股份有限公司（以下简称"公司"）第四届董事会第九 次会议通知已于 2025 年 10 月 23 日通过电话、邮件等方式通知了全体董事。 2、本次会议于 2025 年 10 月 26 日在公司会议室以现场结合通讯方式召开。 3、本次会议由董事长葛文越先生召集并主持，会议应出席董事 9 人，实际 出席董事 9 人，其中 7 名董事以通讯方式出席。公司高级管理人员列席了本次会 议。 4、本次会议的召集、召开符合《中华人民共和国公司法》等法律、法规、 规范性文件和《公司章程》的有关规定，会议合法、有效。 二、董事会会议审议情况 经与会董事充分讨论，本次会议审议并通过了以下议案： （一）审议通过《关于<2025 年第三季度报告>的议案》 经与会董事审议，公司 2025 年第三季度报告的编制和审核程序符合法律、 行政法规和中国证监会的规定，报告内容真实、准确、完整地反映了公司的实际 情况，不存在任何虚假记载、误导性陈述或者重大遗漏。 具体内容详见公司同日在巨潮资讯网（ ...

证券代码：300899 证券简称：*ST凯鑫 公告编号：2025-044 上海凯鑫分离技术股份有限公司 董事会审议利润分配方案后至实施前，公司股本如发生变动，将按照分配总 额不变的原则对分配比例进行调整。 二、利润分配方案的合理性、合法性、合规性 本次利润分配方案预计分红金额 24,875,551.74 元（含税），分红金额未超 过前三季度合并报表归属于上市公司股东的净利润，符合《中华人民共和国公司 法》《上市公司监管指引第 3 号——上市公司现金分红》《深圳证券交易所创业 板股票上市规则》等法律法规、规范性文件及《公司章程》的规定，是在保证公 司正常经营和长远发展的前提下拟定的，符合公司的利润分配政策和股东回报规 划，具备合法性、合规性、合理性。 关于 2025 年前三季度利润分配方案的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 上海凯鑫分离技术股份有限公司（以下简称"公司"）于 2025 年 10 月 26 日召开第四届董事会第九次会议，审议通过了《关于 2025 年前三季度利润分配 方案的议案》，该议案尚需提交 2025 年第三次临时股东会审议 ...

Financial Performance - The company's operating revenue for Q3 2025 was ¥23,369,002.94, a decrease of 35.72% compared to the same period last year, while the year-to-date revenue increased by 93.16% to ¥151,237,146.20[5] - The net profit attributable to shareholders for Q3 2025 was -¥706,311.22, representing a decline of 112.00% year-on-year, while the year-to-date net profit increased by 334.55% to ¥30,947,111.10[5] - The basic earnings per share for Q3 2025 was -¥0.0111, down 112.03% from the previous year, while the year-to-date figure rose by 334.38% to ¥0.4852[5] - The weighted average return on equity for Q3 2025 was -0.11%, a decrease of 1.03% compared to the same period last year, while the year-to-date return increased by 3.67% to 4.76%[5] - Total operating revenue for the current period reached ¥151,237,146.20, a significant increase from ¥78,298,256.78 in the previous period, representing an increase of approximately 93.1%[20] - Net profit for the current period was ¥30,965,846.87, up from ¥7,090,430.91 in the previous period, indicating a growth of approximately 336.5%[21] - The total comprehensive income for the period attributable to the parent company was ¥31,006,529.65, a significant increase from ¥7,144,782.77 in the previous period, reflecting a growth of approximately 334%[22] - Basic and diluted earnings per share increased to ¥0.4852 from ¥0.1117, representing an increase of about 335%[22] Assets and Liabilities - Total assets at the end of Q3 2025 were ¥770,009,050.53, a decrease of 2.79% from the end of the previous year[5] - Total assets decreased to ¥770,009,050.53 from ¥792,142,257.20, a decline of approximately 2.8%[19] - Total liabilities decreased to ¥103,635,257.29 from ¥158,044,621.97, a reduction of about 34.5%[19] - The company's inventory decreased to ¥97,336,035.53 from ¥126,681,226.39, a decline of approximately 23.2%[17] - Long-term receivables decreased by 52.29% to CNY 1,291,162.42, mainly due to the annual reduction of financing lease payments[11] - Fixed assets increased by 30.13% to CNY 32,783,998.19, primarily due to the transfer of construction projects to fixed assets[11] - Intangible assets surged by 841.81% to CNY 60,335,077.69, mainly due to the addition of proprietary technologies[11] - Other current assets increased by 255.58% to CNY 5,767,180.51, primarily due to prepaid corporate income tax[11] - The total owner's equity increased to ¥666,373,793.24 from ¥634,097,635.23, representing a growth of about 5.1%[19] Cash Flow - The company's cash flow from operating activities was -¥19,292,024.88 year-to-date, a decline of 141.39% compared to the previous year[5] - Net cash flow from operating activities was negative at -¥19,292,024.88, a decline from a positive cash flow of ¥46,612,158.41 in the previous period[23] - Cash inflow from investment activities totaled ¥417,009,724.84, down from ¥881,061,863.86, indicating a decrease of approximately 53%[24] - The net cash flow from investment activities was ¥32,097,410.44, compared to ¥87,688,385.54 in the previous period, a decrease of about 63%[24] - Cash and cash equivalents at the end of the period amounted to ¥138,292,426.06, down from ¥248,459,921.71, a decline of approximately 44%[24] - The company reported cash outflows from financing activities of ¥2,086,635.19, compared to ¥25,309,554.26 in the previous period, indicating a reduction in cash outflows[24] - The company received cash from investment activities of ¥1,250,000.00, marking the first instance of cash inflow from this category in the current reporting period[24] Government Support and Non-Recurring Items - The company received government subsidies amounting to ¥891,345.28, which positively impacted its financial performance[7] - Non-recurring gains and losses for the year-to-date amounted to ¥3,022,980.30, with a significant portion attributed to the fair value changes of financial assets[7] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 4,373, with the largest shareholder holding 22.48%[15] Investment and Financial Income - The company reported a 66.83% decrease in investment income to CNY 1,305,466.43, due to a reduction in structured deposit investments[12] - The company experienced a 240.47% increase in financial income, resulting in financial expenses decreasing to -CNY 2,379,812.89[12]

Group 1 - The core transaction involved *ST Kaixin, with a total of 500,000 shares traded on October 17, resulting in a transaction value of 13.75 million yuan, which accounted for 49.48% of the total trading volume for that day [1][2] - The transaction price was set at 27.5 yuan per share, reflecting a discount of 0.36% compared to the market closing price of 27.6 yuan [1][2]

格隆汇10月16日丨*ST凯鑫（维权）(300899.SZ)公布，截至本公告披露日，股东张蔚女士持有上海凯鑫 分离技术股份有限公司股份137,997股（占公司总股本0.2164%），拟在本减持计划披露之日起15个交易 日后的3个月内以集中竞价方式合计减持本公司股份不超过137,997股，即不超过公司总股本的0.2164% （减持期间如公司有送股、资本公积金转增股本等导致持股数量变化，则减持数量进行相应调整，但减 持股份占公司总股本的比例不变）。 ...

Group 1 - The core point of the news is that *ST Kaixin announced a share reduction plan by shareholder Zhang Wei, who holds approximately 140,000 shares, representing 0.2164% of the company's total share capital, intending to reduce shares within three months after the disclosure of the plan [1] - As of the announcement date, *ST Kaixin's market capitalization is reported to be 1.8 billion yuan [2] - The company's revenue composition for the year 2024 is entirely from the specialized equipment manufacturing industry, accounting for 100.0% [1]

Core Viewpoint - Shareholder Zhang Wei of *ST Kaixin plans to reduce his stake in the company due to personal financial needs, intending to sell up to 138,000 shares, which represents 0.2164% of the total share capital [1] Summary by Relevant Sections - **Shareholder Information** - Zhang Wei currently holds 138,000 shares of *ST Kaixin, accounting for 0.2164% of the company's total shares [1] - **Reduction Plan** - The reduction plan will commence 15 trading days after the announcement and will take place over a period of three months, with a maximum reduction of 138,000 shares [1]

证券代码：300899 证券简称：*ST凯鑫 公告编号：2025-041 上海凯鑫分离技术股份有限公司 （一）股东名称：张蔚 （二）张蔚女士通过非交易过户取得公司的股份，并严格遵守非交易过户时 的承诺。股东持股情况如下： | 姓名 | 持股数量（股） | 占总股本的比例（%） | | --- | --- | --- | | 张蔚 | 137,997 | 0.2164 | 二、本次减持计划的主要内容 关于股东股份减持计划的预披露公告 公司股东张蔚保证向本公司提供的信息披露内容真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 截至本公告披露日，股东张蔚女士持有上海凯鑫分离技术股份有限公司（以 下简称"公司"或"上海凯鑫"）股份 137,997 股（占公司总股本 0.2164%），拟在 本减持计划披露之日起 15 个交易日后的 3 个月内以集中竞价方式合计减持本公 司股份不超过 137,997 股，即不超过公司总股本的 0.2164%（减持期间如公司有 送股、资本公积金转增股本等导致持股数量变化，则减持数量进行相应调整，但 减持 ...

Group 1 - Dongxing Medical plans to acquire 90% equity of Wuhan Yijiaobao for cash, which is expected to constitute a major asset restructuring [1] - Fosun Pharma's subsidiary plans to transfer 100% equity of Shanghai Cloning, with a transaction value of up to 1.256 billion yuan [1] Group 2 - *ST Songfa's subsidiary signed a shipbuilding contract worth approximately 400-600 million USD for four VLCCs, expected delivery between late 2026 and mid-2027 [3] - Qibin Group obtained financing support of up to 90 million yuan for share repurchase [4] Group 3 - Shapuaisi's shareholder plans to reduce holdings by up to 3% of the company's total shares [5] - *ST Kaixin intends to use up to 310 million yuan for cash management in safe and liquid financial products [6] Group 4 - Junchen Technology's shareholders plan to transfer 2.5% of the company's shares due to personal funding needs [7] - Jingliang Holdings received an administrative regulatory measure from Hainan Securities Regulatory Bureau for improper revenue recognition involving 299 million yuan [7] Group 5 - Tongcheng Holdings received a cash dividend of 24.6643 million yuan from Changsha Bank [9] - Shenyang Chemical appointed Chen Liguo as the new general manager [10] Group 6 - Huaguang Huaneng signed a contract for a 160 million yuan waste heat boiler project [15] - Shuxian Valley's subsidiary completed the re-registration of a health food product [16] Group 7 - Xuanta Pharmaceutical's new specification for a diabetes treatment drug was approved [17] - Panlong Pharmaceutical's application for a pain relief gel patch was accepted by the drug regulatory authority [18] Group 8 - Zhiguang Electric's subsidiary won a procurement contract worth 164 million yuan for a storage system [19] - Chitianhua's production facility resumed operations after maintenance [20] Group 9 - Haitong Development's application for a specific A-share issuance was accepted by the Shanghai Stock Exchange, aiming to raise 210 million yuan [20] - Risheng Technology's shareholders plan to transfer 4.02% of the company's shares [33] Group 10 - Pingmei Shares' controlling shareholder plans a strategic restructuring with Henan Energy Group [35] - Shenghui Integration's controlling shareholder committed not to reduce shareholdings for 12 months [37] Group 11 - Agricultural Bank and Bank of China will no longer establish supervisory boards, with their functions transferred to the audit committees [39][40] - Dongfang Yuhong's subsidiary signed a contract for a seawater pipeline project worth 2.524 billion USD [40][41] Group 12 - Ganfeng Lithium plans to introduce investors for a capital increase of up to 2.5 billion yuan [50] - Hanyu Pharmaceutical intends to raise up to 968 million yuan for various projects [51]

Core Viewpoint - *ST Kaixin announced the approval of a proposal to use up to 130 million yuan of its own funds and up to 180 million yuan of temporarily idle raised funds for cash management [1] Group 1: Financial Management - The funds will primarily be used for short-term financial products with high safety and liquidity, such as large bank deposits and structured deposits [1] - The effective period for these investments is within 12 months, and the funds can be rolled over within the approved limits [1] Group 2: Market Considerations - The company will engage in these investments based on economic conditions and changes in the financial market, but acknowledges that market fluctuations may impact these investments [1] - It is emphasized that these investment activities must not affect the progress of fundraising projects and the company's normal production and operations [1]